Botulinum toxin type A injection in alleviating postoperative pain and improving quality of life in lower extremity limb lengthening and deformity correction: a pilot study
Related Experiment Video
Updated: Jun 22, 2026

Targeted Muscle Reinnervation: Surgical Protocol for a Randomized Controlled Trial in Postamputation Pain
Published on: March 8, 2024
Reggie C Hamdy1, Kathleen Montpetit, Ellen M Raney
1Shriners Hospital for Children, Montreal, Quebec, Canada. rhamdy@shriners.mcgill.ca
Insights
Botulinum toxin type A (BtX-A) injections show promise in reducing pain and improving quality of life for children undergoing limb lengthening surgery. This pilot study found BtX-A safe and effective, warranting further investigation.
Area of Science:
- Orthopedic surgery
- Pediatric orthopedics
- Pain management
Background:
- Ilizarov technique is common for pediatric lower limb lengthening and deformity correction.
- Postoperative pain significantly impacts children's quality of life and mobility.
- Limited evidence exists for botulinum toxin type A (BtX-A) use in this context.
Purpose of the Study:
- Assess feasibility of a randomized clinical trial for children undergoing limb correction.
- Provide preliminary evidence on the efficacy of BtX-A for pain management in this population.
Main Methods:
- A pilot randomized controlled trial involving 52 pediatric patients (mean age 13.7 years).
- Patients received either BtX-A or a saline placebo during surgery.
- Outcomes measured included pain, medication use, quality of life, and functional mobility.
Main Results:
- BtX-A group showed trends toward lower pain and reduced parenteral pain medication use (first 4 days).
- Improved quality of life and functional mobility scores were observed in the BtX-A group.
- All adverse events were expected complications; no serious adverse events related to BtX-A were reported.
Conclusions:
- The study successfully established the feasibility of a randomized controlled trial design.
- BtX-A injections appear safe and effective for pain reduction and functional improvement in pediatric limb correction.
- A larger study is ongoing to confirm these promising preliminary findings.
Background:
The Ilizarov technique is commonly used for lengthening and deformity corrections of the lower limbs in children. Postoperative pain can be significant, affecting quality of life and functional mobility, and often requiring prolonged medication use. Several studies have investigated the antinociceptive actions of botulinum toxin type A (BtX-A), yet evidence for its use in this population is limited. The objectives were to (1) establish the feasibility of a randomized clinical trial in children undergoing limb lengthening or deformity correction and (2) provide preliminary evidence of the beneficial effects of BtX-A in this population.
Methods:
Fifty-two patients with a mean age of 13.7 years (range, 5 to 21 y) were randomized to receive either BtX-A or an equivalent volume of sterile saline solution (placebo group), as a single dose during the surgical procedure. Pain, medication use, quality of life, and functional mobility outcomes were assessed in all patients. Adverse events were reported for all patients and classified as minor or major.
Results:
Differences between groups did not reach statistical significance; however, pain at mid-distraction was found to be slightly lower in the BtX-A group, as compared with the placebo group. Patients in the BtX-A group used less parenteral pain medication in the first 4 days after the surgery, had higher quality of life scores at 3 of the 5 time points assessed, and slightly higher functional mobility scores. All adverse events were expected complications of the lengthening process. No event was considered to be a serious adverse event related to the BtX-A injection itself. There was a trend toward fewer major adverse events in the BtX-A group.
Conclusions:
This pilot study established the feasibility of a randomized controlled trial design for in this population. Its findings indicate that BtX-A injections appear to be safe and effective for reducing pain and improving the quality of life and functional mobility of children undergoing lengthening or deformity corrections of the lower limbs. A larger-scale study is currently underway to confirm these preliminary findings.
Related Concept Videos
Skeletal Muscle Relaxants: Therapeutic Uses
Local Anesthetics: Clinical Application as Spinal Anesthesia
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
